Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Efficacy of moxifloxacin in TB resistant to isoniazid Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Tuberculosis 1995–2004: evaluation of the resistance of mycobacterium tuberculosis to anti-TBC drugs in Greece Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
High-dose rifampicin and rifapentine in tuberculosis treatment Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Monoresistance to rifampicin – a problem for treatment results? Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016
Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Rifampicin and INH monoresistance prevalence among Iraqi smear positive pulmonary tuberculosis cases Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016